Wille Finance

Wille Finance is a Swiss-based multi-family office located in Zug, focusing on a diverse range of investment opportunities. Established in 2007, the firm invests primarily in private equity, real estate, digital media, and listed assets. For private equity, Wille Finance engages in both early-stage investments, particularly in Life Sciences and Information and Communication Technology, and late-stage investments. In real estate, the firm adopts a long-term, value-add strategy concentrated on major European cities. Its digital media investments emphasize companies that blend media, content, and technology. Additionally, Wille Finance manages a net-long portfolio in listed assets, guided by an experienced executive management team.

Gergely Paljak

Tech Investor

10 past transactions

Edflex

Series B in 2023
Online learning resources search engine

Invasight

Seed Round in 2022
Invasight is a clinical biotech company that focused on revolutionizing cell invasion research. The company was founded in 2019 and is headquartered in Zurich, Switzerland.

Warehousing1

Series A in 2022
Warehousing1 is building the number one warehousing and distribution network in Europe. Companies can utilize the innovative platform to find ideal warehousing solutions anywhere, manage them digitally and optimize processes by gaining real-time visibility and data transparency.

Storebox

Series B in 2021
store.me is the Airbnb for storage space. It connects people providing or seeking storage space. The platform enables to rent underutilized cellars, garages or other empty rooms. On the other hand, people can find a suitable storage space or a garage in the desired area in Austria. Price, rental period and date are agreed directly between the lessor and the leaser. Apart from the integrated storage space management for lessors the platform also provides flexible insurance packages for the stored goods as well as transport and cleaning services.

Fertilly

Seed Round in 2021
Developer of a digital health platform intended to assist women, men, and couples throughout their fertility journeys. The company's platform helps patients to find the right fertility clinic and also accompanies the patients from the first consultation to the birth of their dream child, enabling patients to have the desire for children, artificial insemination, and social freezing during pregnancy.

Oculis

Series C in 2021
Oculis is a clinical-stage biotechnology company dedicated to developing innovative topical treatments for ophthalmic diseases affecting both the anterior and posterior segments of the eye. Founded in 2003 and headquartered in Reykjavik, Iceland, Oculis utilizes a unique drug delivery platform that enhances drug absorption through a novel technique, enabling effective treatment of conditions such as diabetic macular edema, uveitis, chronic dry eye syndrome, glaucoma, and diabetic retinopathy with simple eye drops. This approach allows for non-invasive treatment of diseases at the back of the eye, traditionally requiring more complex methods, while also reducing the frequency of applications needed for anterior eye conditions. Oculis is committed to improving patient outcomes and enhancing the quality of life for individuals with vision-related health issues.

T3 Pharmaceuticals

Series C in 2020
T3 Pharmaceuticals AG is a biopharmaceutical company based in Basel, Switzerland, founded in 2015. The company focuses on the research and development of bacteria-based therapies specifically designed for cancer treatment. Recognizing the ongoing need for innovative solutions in oncology, T3 Pharmaceuticals aims to enhance the lives of cancer patients by creating highly specific and efficient treatments using live bacteria. Through its work, the company seeks to address the limitations of conventional therapies and contribute to the advancement of novel cancer medicines.

Hillo

Seed Round in 2020
Hillo designs, develops, and operates artificial intelligence platform to transform diabetic patient's lives. The company develops tools to anticipate blood glucose level. Hillo was founded in 2016 and is based in Palaiseau, France.

ImmunOs Therapeutics

Series A in 2019
ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of novel human immunomodulatory proteins aimed at enhancing cancer treatment and addressing autoimmune diseases. By focusing on next-generation therapeutics, ImmunOs aims to create drugs that not only exhibit direct anti-tumor effects but also remodel the tumor microenvironment. Additionally, the company is developing antibodies designed to block the activation of specific HLA molecules associated with autoimmune conditions. Through its innovative approach, ImmunOs Therapeutics seeks to improve the lives of patients suffering from serious diseases.

Hillo

Pre Seed Round in 2018
Hillo designs, develops, and operates artificial intelligence platform to transform diabetic patient's lives. The company develops tools to anticipate blood glucose level. Hillo was founded in 2016 and is based in Palaiseau, France.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.